A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis

Inclusion Criteria: * diagnosed as myasthenia gravis (MG) by clinical diagnosis * QMG scores ≥7 at the time of enrollment * basic treatment drugs are mainly glucocorticoids, and the efficacy of glucocorticoid therapy was not sufficient Exclusion Criteria: * receiving blood purification therapy or immunoglobulin therapy within 8 weeks before the study * QMG swallowing function score ≥ 2 points or QMG vital capacity = 3 * abnormal hepatic functions * uncontrolled diabetes patients * hyperkalemia patients * immuno-inhibitors are forbidden due to malignancy, history of malignancy or history of HIV infection * patients who are allergic to Tacrolimus or macrolide antibiotics * receiving other immuno-inhibitors within 12 weeks